Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TIBSOVO vs CLOLAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isocitrate dehydrogenase-2 (IDH2) inhibitor; targets mutant IDH2 isoforms to reduce 2-hydroxyglutarate (2-HG) levels, promoting myeloid differentiation.
Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.
Acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation, relapsed or refractory,Acute myeloid leukemia (AML) with an IDH2 mutation, newly diagnosed in patients ≥75 years or with comorbidities ineligible for intensive induction chemotherapy
FDA: Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years.,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML) in blast crisis.
500 mg orally once daily taken with or without food.
5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.
Terminal elimination half-life: 50-60 hours, supporting once-daily dosing with steady-state reached in approximately 2 weeks.
Terminal elimination half-life approximately 5.2 hours in patients with normal renal function; prolonged in renal impairment (up to 9.8 hours with Cr Cl <60 m L/min) and in elderly; clinical context: supports once-daily dosing adjustment for renal function.
Primarily metabolized by CYP3A4; also a minor substrate of CYP2C19, CYP2D6, and UGT1A1.
Clofarabine is partially metabolized by deamination via cytidine deaminase (CDA) to inactive 6-keto-clofarabine. Approximately 50-60% of the drug is excreted unchanged in urine.
Primarily hepatic metabolism (CYP3A4) and fecal excretion (77% unchanged and metabolites); renal elimination accounts for <1% of absorbed dose.
Renal: 50-60% as unchanged drug; biliary/fecal: minimal (<5%)
>99.9% bound, primarily to serum albumin.
47% bound to human plasma proteins, primarily albumin.
Volume of distribution (Vd/F): approximately 2.2 L/kg (range 1.7-2.8), indicating extensive extravascular distribution.
Central Vd approximately 172 L/m² (extensive tissue distribution); in L/kg: ~4.6 L/kg (assuming 70 kg patient with BSA 1.73 m²). Clinical meaning: indicates wide distribution into total body water and tissues, exceeding total body water.
Estimated absolute bioavailability is approximately 60-70% after oral administration.
Intravenous: 100% (only route of administration); oral: not available (no oral formulation).
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or dialysis.
Cr Cl >= 60 m L/min: no adjustment. Cr Cl 30-59 m L/min: reduce dose by 20%. Cr Cl < 30 m L/min: contraindicated.
No dose adjustment for mild hepatic impairment (Child-Pugh class A). Moderate or severe hepatic impairment (Child-Pugh class B or C) has not been studied; use with caution and monitor for adverse effects.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) and consider dose reduction based on tolerability.
Safety and effectiveness have not been established in pediatric patients; no dosing recommendations available.
1-21 years: 5 mg/m2 IV over 2 hours daily for 5 days every 28 days; reduce dose by 50% in patients with renal impairment.
No specific dose adjustment recommended; clinical studies included patients aged 65 years and older, but no overall differences in safety or efficacy were observed compared to younger patients.
No specific dose adjustment, but monitor renal function closely due to age-related decline and increased risk of toxicity.
None
WARNING: HEMATOLOGIC TOXICITY, INFECTION, AND HEPATIC TOXICITY. Clolar suppresses bone marrow function, causing severe neutropenia, thrombocytopenia, and anemia. Fatal infections have occurred. Hepatic toxicity, including hepatic failure and death, has been reported. Monitor blood counts and liver function frequently.
Differentiation syndrome (can be fatal, treat with corticosteroids and hemodynamic support),QT prolongation (monitor ECG and electrolytes),Embryo-fetal toxicity
Bone marrow suppression: severe neutropenia, thrombocytopenia, and anemia require close monitoring. Infections: serious and fatal infections (bacterial, fungal, viral) may occur. Hepatic toxicity: elevation of liver enzymes, bilirubin, and hepatic veno-occlusive disease. Renal toxicity: increased creatinine, hematuria, and hemolytic uremic syndrome-like reactions. Cardiac toxicity: pericardial effusion, hypotension, and ventricular dysfunction. Tumor lysis syndrome. Hypersensitivity reactions. Use in pregnancy: embryo-fetal toxicity. Vaccination: avoid live vaccines.
None known
Absolute: Hypersensitivity to clofarabine or any component of the formulation. Relative: Severe hepatic impairment (bilirubin >3 mg/d L or transaminases >5x ULN). Severe renal impairment (creatinine clearance <30 m L/min).
Take on an empty stomach (no food for at least 1 hour before or 2 hours after). Avoid grapefruit and grapefruit juice (CYP3A4 inhibition). High-fat meals significantly increase absorption; avoid concomitant intake.
No specific food interactions are documented. However, maintain adequate hydration to reduce risk of nephrotoxicity and tumor lysis syndrome. Avoid grapefruit and grapefruit juice as they may affect metabolism via CYP3A4 (theoretical concern, though clofarabine is primarily renally excreted).
Based on animal studies and its mechanism of action (IDH1 inhibition), TIBSOVO (ivosidenib) may cause fetal harm. No adequate human data exist. It is teratogenic in rats at exposures below the clinical dose. Avoid use in pregnancy unless benefit outweighs risk. Confirm negative pregnancy test before initiation. First trimester: risk of major malformations unknown but potential. Second/third trimester: potential for fetal growth restriction and oligohydramnios due to effects on cellular metabolism. Use effective contraception during treatment and for at least 1 month after the last dose.
Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered during pregnancy. In the first trimester, there is a significant risk of embryolethality and teratogenicity (structural anomalies). In the second and third trimesters, fetal growth restriction and central nervous system damage may occur. Pregnancy must be excluded before initiation.
No data on presence in human milk, effects on breastfed infants, or milk production. Due to potential for serious adverse reactions, breastfeedin is not recommended during treatment and for at least 1 month after the last dose. M/P ratio not available.
No data available on the excretion of clofarabine into breast milk or its effects on the nursing infant. Due to potential for serious adverse reactions (e.g., myelosuppression, gastrointestinal toxicity), breastfeeding is contraindicated during therapy and for at least 3 months after the last dose. M/P ratio is unknown.
No formal studies in pregnancy. Dose adjustments for pregnancy-induced physiologic changes (increased plasma volume, renal clearance, hepatic metabolism) are not defined. Standard dosing (500 mg orally once daily) is used; however, close monitoring for toxicity and efficacy is warranted. Use only if clearly needed after consideration of risks.
There are no established dose adjustments for clofarabine during pregnancy, as use is contraindicated. Physiological changes in pregnancy (e.g., increased plasma volume, altered renal clearance) may affect pharmacokinetics, but no dosing guidelines exist. If inadvertent exposure occurs, immediate discontinuation is recommended and the pregnancy should be managed by a maternal-fetal medicine specialist.
TIBSOVO (ivosidenib) is an IDH1 inhibitor indicated for IDH1-mutant acute myeloid leukemia (AML) and cholangiocarcinoma. Monitor for differentiation syndrome, which can be fatal; treat with corticosteroids and hemodynamic support. ECG monitoring for QTc prolongation is required; avoid concomitant use with strong CYP3A4 inhibitors or inducers. Assess liver function before and during therapy. Administer on an empty stomach at least 1 hour before or 2 hours after a meal.
Clolar (clofarabine) is a purine nucleoside analog indicated for pediatric relapsed/refractory acute lymphoblastic leukemia. Key pearls: (1) Monitor for systemic inflammatory response syndrome (SIRS) and capillary leak syndrome; premedicate with corticosteroids. (2) Requires aggressive hydration and allopurinol for tumor lysis prophylaxis. (3) Dose reductions needed for renal impairment (Cr Cl < 60 m L/min). (4) Avoid live vaccines during and after treatment.
Take TIBSOVO on an empty stomach, at least 1 hour before or 2 hours after eating.,Do not crush or chew the tablets; swallow them whole.,Tell your doctor immediately if you experience fever, cough, difficulty breathing, or swelling (signs of differentiation syndrome).,Report any symptoms of heart rhythm changes (dizziness, fainting, chest pain) or liver problems (yellowing skin, dark urine, abdominal pain).,Avoid grapefruit and grapefruit juice during treatment.,Inform all healthcare providers that you are taking TIBSOVO.
Clolar is a chemotherapy drug used to treat a type of leukemia in children that has not responded to other treatments.,You may experience side effects like fever, nausea, vomiting, diarrhea, and skin rashes. Report any signs of infection or unusual bleeding.,Drink plenty of fluids as directed to prevent kidney problems. You may receive IV fluids before and after treatment.,Avoid vaccinations without doctor approval, as live vaccines are not safe during treatment.,This drug can cause severe reactions including organ inflammation and fluid retention; seek immediate medical help if you have difficulty breathing, rapid weight gain, or swelling.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TIBSOVO vs CLOLAR, answered by our medical review team.
TIBSOVO is a Antineoplastic Agent that works by Isocitrate dehydrogenase-2 (IDH2) inhibitor; targets mutant IDH2 isoforms to reduce 2-hydroxyglutarate (2-HG) levels, promoting myeloid differentiation.. CLOLAR is a Antineoplastic Agent that works by Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TIBSOVO and CLOLAR depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TIBSOVO is: 500 mg orally once daily taken with or without food.. The standard adult dose of CLOLAR is: 5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TIBSOVO and CLOLAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TIBSOVO is classified as Category C. Based on animal studies and its mechanism of action (IDH1 inhibition), TIBSOVO (ivosidenib) may cause fetal harm. No adequate human data exist. It is teratogenic in rats at exposur. CLOLAR is classified as Category C. Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered du. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.